Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Search results are limited to:
Abstract Book of the 7th European Myeloma Network Meeting, Prague, 16-18 April 2026
Vol. 111 No. s2
Advanced filters
Search the full archive
Keyword matches

P72 | BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY AL AMYLOIDOSIS: CLINICAL EXPERIENCE IN TWO ACADEMIC BELGIAN CENTERS (202 Online Views)

M.C. Vekemans1, O. Rizzo2, N. Meuleman2

1 Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Bruxelles, Belgium
2 Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Belgium
AL Amyloidosis Multiple Myeloma anti-BCMA

P33 | ARLOCABTAGENE AUTOLEUCEL, A GPRC5D-TARGETED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1 SAFETY AND EFFICACY RESULTS IN PATIENTS WITH 1–3 PRIOR REGIMENS (602 Online Views)

S. Bal1, M. Htut2, J. Berdeja3, L. Anderson4, A. Rossi5, T. Gregory6, L. Costa1, H. Hu7, Z. Guo7, J. Chen7, K. Jordahl7, N. Sarkis7, S. Ziyad7, W.M. Kao7, A. Kaeding7, M. Burgess7, O. Nadeem8

1 University of Alabama at Birmingham, USA
2 City of Hope Comprehensive Cancer Center, Duarte, USA
3 Greco-Hainsworth Tennessee Oncology Center for Research, Nashville, USA
4 Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, USA
5 Icahn School of Medicine at Mount Sinai, New York, USA
6 Colorado Blood Cancer Institute, Sarah Cannon Cancer Network, Denver, USA
7 Bristol Myers Squibb, Princeton, USA
8 Dana-Farber Cancer Institute, Boston, USA
RRMM CAR-T cells BCMA

P34 | CEVOSTAMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: BIOMARKER ANALYSES FROM CAMMA 1 ARM B (246 Online Views)

R. Popat1, S. Harrison2, C. H. Riley3, H.S. Mian4, A. Spencer5, N. Lavi6, L. Paris7, T. Jelínek8, M. Szarejko9, S. Grosicki10, K. Kim11, I. Sandhu12, S. Chebon13, T. Tyagi14, P. Sewpaul15, L. Richardson15, K. Trunzer13, A. Mishra14, S. Trudel16

1 University College London Hospitals NHS Foundation Trust, UK
2 Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, Melbourne University and The Royal Melbourne Hospital, Australia
3 Rigshospitalet, Copenhagen, Denmark
4 McMaster University, Hamilton, Canada
5 Alfred Health-Monash University, Melbourne, Australia
6 Rambam Health Care Campus, Haifa, Israel
7 ASST Papa Giovanni XXIII, Bergamo, Italy
8 Department of Hematooncology, University Hospital Ostrava and University of Ostrava, Czech Republic
9 Medical University of Gdansk, Poland
10 Medical University of Silesia, Katowice, Poland
11 Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea
12 Cross Cancer Institute, University of Alberta, Edmonton, Canada
13 F. Hoffmann-La Roche Ltd, Basel, Switzerland
14 Genentech, Inc, South San Francisco, USA
15 Roche Products Ltd, Welwyn, UK
16 Princess Margaret Cancer Centre and University of Toronto, Canada
CAMMA 1 study BCMA Multiple Myeloma

P35 | PROLONGED ELRANATAMAB TREATMENT INTERRUPTION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MagnetisMM-3 RETROSPECTIVE ANALYSIS (251 Online Views)

E. Searle1|2, A. Lesokhin3, R. Niesvizky4, B. Arnulf5, S. Larson6, C.. Strouse7, C. Fernandez De Larrea8, D. Vesole9, Y. Nagai10, S.T. Sullivan11, E. Leip11, N. Bahlis12

1 The Christie NHS Foundation Trust, Manchester, UK
2 University of Manchester, UK
3 Memorial Sloan Kettering Cancer Center, New York, USA
4 Weill Cornell Medicine/New York Presbyterian Hospital, USA
5 Hôpital Saint-Louis, APHP, Université Paris, France
6 UCLA Medical Center, Santa Monica, USA
7 Carver College of Medicine,Iowa City, USA
8 Hospital Clínic, Barcelona, Spain
9 John Theurer Cancer Center, Hackensack, USA
10 Kobe City Medical Center General Hospital, Japan
11 Pfizer Inc, Cambridge, USA
12 Arnie Charbonneau Cancer Institute, Calgary, Canada
RRMM BCMA MagnetisMM-3

P62 | INITIAL EXPERIENCE WITH IDECABTAGENE VICLEUCEL IN PATIENTS WITH REFRACTORY MULTIPLE MYELOMA: CASE SERIES IN A TERTIARY CARE HOSPITAL (210 Online Views)

L. Piquer Monsonis1, A. Pérez Montaña1, J.M. Sánchez Raga1, A. Sampol Mayol1, M. Galí Sampol1, R. Ferrero Guillén1, E. Serrasoles Alemany1, M. Remezal Serrano1, A. Alonso Carballo1, S. Montolio Chiva1, P. Gómez Fernández1, J. Domínguez Esteve2, A. Horrillo Orejudo2

1 Department of Hematology and Hemotherapy, Hospital Universitari Son Espases, Palma de Mallorca, Spain
2 Hospital Comarcal de Inca, Spain
BCMA Decabtagene vicleucel Multiple Myeloma
Title matches

P37 | ANALYSIS OF PATIENTS WITH PRIOR BCMA-TARGETED THERAPY AND THOSE ACHIEVING COMPLETE RESPONSE IN REALiTAL: A MULTI-COUNTRY OBSERVATIONAL STUDY OF TALQUETAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS (327 Online Views)

R. Popat1, K.M. Kortüm2, H. Magen3, V. Mykytiv4, C. Liberatore5, E. Zamagni6, M.C. Da Vià7, E. Antonioli8, M. Hansson9, D. Santra10, D. Greer10, K. Subrt11, P. Hu11, E. Aeby11, N. Francella11, N.M. Suñe11, A. Perrot12, K. Uttervall13

1 University College London Hospitals NHS Foundation Trust, UK
2 University Hospital of Würzburg, Germany
3 Tel Aviv University, Israel
4 Cork University Hospital, Ireland
5 Ospedale Santo Spirito, Pescara, Italy
6 University of Bologna, Italy
7 IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
8 Careggi Hospital and University of Florence, Italy
9 Sahlgrenska University Hospital, Gothenburg, Sweden
10 Parexel International
11 Johnson & Johnson
12 Université de Toulouse, France
13 Karolinska University Hospital, Stockholm, Sweden
Multiple Myeloma REALiTAL Trial RRMM

P61 | IMMUNE EFFECTOR CELL COLITIS DURING TREATMENT WITH AN ANTI-BCMA BISPECIFIC ANTIBODIES (225 Online Views)

M. Minnema1, H. Fidder2, R. Oostvogels1, V. Biemans2

1 Department of Hematology, UMC Utrecht, The Netherlands
2 Department of Gastroenterology, UMC Utrecht, The Netherlands
Multiple Myeloma Colitis Bispecific antibodies
Text matches

P56 | BASELINE IMMUNE PROFILE PREDICTS RESPONSE TO BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD MONOCENTRIC EXPLORATORY ANALYSIS (216 Online Views)

First match: ... sease. Sequencing variables included number of prior therapy lines and previous BCMA-targeted exposure. Correlations were assessed using Spearman’s rho; longitudina ...

R. Della Pepa1, A. Leone1, L. Esposito1, G.L. D'Elia1, V. Cerbone2, M. Raia2, G. Scalia2, F. Pane1

1 Division of Hematology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Italy
2 Clinical and Experimental Cytometry Unit, Centre for Advanced Biotechnology Franco Salvatore, CEINGE Biotecnologie Avanzate, Naples, Italy

P67 | TALQUETAMAB INDUCES DEEP RESPONSES IN HEAVILY PRE-TREATED PATIENTS WITH SYSTEMIC LIGHT-CHAIN AMYLOIDOSIS (253 Online Views)

First match: ... 1;14) was refractory to venetoclax. Three patients relapsed after academic anti-BCMA CAR-T. Additional therapies included ixazomib (2), carfilzomib (1), elotuzumab ...

T. Shragai1|2, M. Ganayem1, Y. Cohen1|2, I. Avivi1|2, E. Lebel3|4, N. Even-Gross Zohar3|4, N. Melamed1, M. Gatt3|4

1 Tel-Aviv Sourasky Medical Center, Israel
2 Tel-Aviv University, Israel
3 Hadassah Medical Center, Jerusalem, Israel
4 Hebrew University, Jerusalem, Israel
Multiple Myeloma AL amyloidosis Talquetamab

P63 | TECLISTAMY (EMN40): A PHASE 2 TRIAL OF TECLISTAMAB IN PATIENTS WITH PREVIOUSLY TREATED LIGHT-CHAIN AL AMYLOIDOSIS (265 Online Views)

First match: ... men for pts with relapsed/refractory disease. Tec, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, has demonstrated deep and durable responses in mult ...

M. Roussel1, E. Kastritis2, S.O. Schönland3, K.M. Kortüm4, B. Arnulf5|6, A. Jaccard1, S. Vara7, M. Doyle7, J.M. Schecter7, A. Carpinteiro8, F. Kwok9, G. Palladini10|11, M.C. Minnema12, M. Boccadoro13, P. Sonneveld14|15

1 Hematology, Centre Hospitalier Universitaire Dupuytren, Limoges, France
2 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece
3 Department of Internal Medicine V, Heidelberg University Hospital, Germany
4 Department of Internal Medicine II, University Hospital of Würzburg, Germany
5 Immuno-Hematology, Saint Louis Hospital, AP-HP, Paris, France
6 Université Paris Cité, France
7 Johnson & Johnson
8 Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Germany
9 Department of Haematology, Westmead Hospital, Sydney, Australia
10 Department of Molecular Medicine, University of Pavia, Italy
11 Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
12 Department of Hematology, University Medical Center Utrecht, The Netherlands
13 European Myeloma Network, Italy
14 Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
15 European Myeloma Network, The Netherlands
AL amyloidosis TeclistAMY (EMN40) trial

P59 | BISPECIFIC ANTIBODIES IN FRAIL AND ELDERLY MULTIPLE MYELOMA PATIENTS WITH ECOG >1: REAL-WORLD IMPACT OF PERFORMANCE STATUS AND DOSE MODIFICATIONS ON OUTCOMES (203 Online Views)

First match: ... o institutional practice. All patients were CAR-T naïve, and a subset had prior BCMA exposure with belantamab mafodotin. Data collection included baseline clinical ...

D. Stoumbos1, A. Antoniou1, K. Lampropoulos1, S. Chrysoglou1, C. Prifti1, M. Panagiotouni1, M. Dadakaridou1, S. Giourgouli2, K. Stefanidis3, M. Kotsopoulou1

1 Metaxa Cancer Hospital, Hematology Clinic and Bone Marrow Transplantation Unit, Athens, Greece
2 Metaxa Cancer Hospital, Nuclear Medicine Department, Athens, Greece
3 Metaxa Cancer Hospital, Department of Radiology, Athens, Greece
Multiple Myeloma Elderly Bispecific antibodies

P58 | TRIAL IN PROGRESS: QUINTESSENTIAL-2 – A PHASE 3 STUDY OF ARLOCABTAGENE AUTOLEUCEL VS. STANDARD OF CARE IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA EXPOSED TO LENALIDOMIDE (257 Online Views)

First match: ... ia, 1-3 pLOT (may include a proteasome inhibitor, IMiD, anti-CD38 antibody, and BCMA-targeted therapy), be exposed to lenalidomide (with ≥2 consecutive cycles, unle ...

E. Lebel1, A. Abdulgawad2, S. Bramanti3, G. Garate4, P.J. Ho5, M. Keränen6, Y. Cohen7, M. Vase8, A. Khot9, I. Kristensen10, R. Leblanc11, C. Lee12, W. Legiec13, H. Magen14, M.V. Mateos15, D. Oh16, L. Pour17, N. Schutz18, A. Spyridonidis19, K. Weisel20, J. Zaucha21, S. Larson22, A. Varshavsky-Yanovsky23, K. Grazioli24, D. Basudhar24, H. Hu24, Y. Meng24, L. Eldjerou24, S. Bal25, S. Harrison9, R. Popat26, M. Raab27, P. Rodriguez-Otero28

1 Hadassah Medical Center, Jerusalem, Israel
2 Christie NHS Foundation Trust, Manchester, UK
3 IRCCS Istituto Clinico Humanitas, Rozzano, Italy
4 Hospital Aleman, Buenos Aires, Argentina
5 Royal Prince Alfred Hospital and University of Sydney, Camperdown, Australia
6 Helsinki University Hospital, Finland
7 Tel Aviv Sourasky Medical Center and Faculty of Medical and Health Sciences, Tel Aviv University, Israel
8 Aarhus Universitetshospital, Midtjylland, Denmark
9 Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Victoria, Australia
10 Odense Universitetshospital, Denmark
11 Hematology-Oncology and Cell Therapy University Institute, Hôpital Maisonneuve-Rosemont Research Center, Université de Montréal, Quebec, Canada
12 Royal Adelaide Hospital, Australia
13 St. John of Dukla Oncology Center of Lublin Land,Poland
14 Department of Hematology, Chaim Sheba Medical Center, Ramat-Gan, Faculty of Medicine, Tel Aviv University, Israel
15 Hospital Universitario de Salamanca, Spain
16 Monash Health and Monash University, Clayton, Victoria, Australia
17 Masaryk University and University Hospital Brno, Czech Republic
18 Hospital Italiano de Buenos Aires, Argentina
19 University Hospital of Patras, Greece
20 University Medical Center Hamburg-Eppendorf, Germany
21 Medical University of Gdańsk and University Clinical Center, Poland
22 UCLA Medical Center, Los Angeles, USA
23 Fox Chase Cancer Center Temple Health, Philadelphia, USA
24 Bristol Myers Squibb, Princeton, USA
25 University of Alabama at Birmingham, USA
26 University College London Hospital, UK
27 Universitaetsklinikum Heidelberg, Germany
28 Clinica Universidad de Navarra, Pamplona, Spain
QUINTESSENTIAL-2 Trial Multiple Myeloma RRMM

P41 | FIRST RESULTS OF REALiTEC-2: SECOND COHORT OF REALiTEC, AN INTERNATIONAL OBSERVATIONAL RETROSPECTIVE STUDY OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN ROUTINE CLINICAL PRACTICE (267 Online Views)

First match: Background. Teclistamab is the first approved bispecific antibody targeting BCMA and CD3 for the treatment of triple class exposed relapsed/refractory multiple myel ...

R. Popat1, K. Uttervall2, K.M. Kortüm3, H. Magen4, M. Hansson5, T. Shragai6, E. Terpos7, C. T. Hansen8, S. Manier9|10, H. Gregersen11, Ø.M. Ottestad12, C. Touzeau13, E. Hatjiharissi14|15, S.L. Farmer16, E. Katodritou17, E. Spanoudakis18, M.Ø. Vase19, C. Liberatore20|21, M. Papathanasiou22, M.K. Angelopoulou7|23, E. Clavero24, R. Kittus25, P. Smirnov25, P. Hu25, D. Santra26, C. Albrecht25, E. Rubio-Azpeitia25, A. Perrot27

1 University College London Hospitals NHS Foundation Trust, UK
2 Karolinska University Hospital, Stockholm, Sweden
3 University Hospital of Würzburg, Germany
4 Tel-Aviv University, Israel
5 Sahlgrenska University Hospital, Gothenburg, Sweden
6 Tel-Aviv Sourasky Medical Center, Israel
7 National and Kapodistrian University of Athens, Greece
8 Odense University Hospital, Denmark
9 University of Lille, France
10 Centre Hospitalier Universitaire Lille, France
11 Aalborg University Hospital, Denmark
12 Akershus University Hospital, Lørenskog, Norway
13 University Hospital Hôtel-Dieu, Nantes, France
14 AHEPA University Hospital, Thessaloniki, Greece
15 Aristotle University of Thessaloniki, Greece
16 Vejle Hospital, Denmark
17 Theagenio Cancer Hospital, Thessaloniki, Greece
18 Democritus University of Thrace, Alexandroupolis, Greece
19 Aarhus University Hospital, Denmark
20 Santo Spirito Hospital, Pescara, Italy
21 "G d'Annunzio" University, Chieti, Italy
22 G Papanicolaou Hospital, Thessaloniki, Greece
23 Laiko General Hospital, Athens, Greece
24 Hospital Universitario Virgen De Las Nieves, Granada, Spain
25 Johnson and Johnson
26 Parexel International on behalf of Johnson & Johnson, Sheffield, UK
27 Université de Toulouse, France
REALiTEC-2 Trial RRMM Teclistamab

P50 | INPATIENT VS. OUTPATIENT TREATMENT MANAGEMENT WITH TECLISTAMAB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A COST AND HEALTHCARE RESOURCE UTILIZATION ANALYSIS (241 Online Views)

First match: Introduction. Teclistamab is a first-in-class CD3xBCMA-targeting bispecific antibody, indicated for the treatment of triple-class exposed relapsed and refractory mu ...

N.W.C.J. Van De Donk1, R. Wester2, I. Nijhof3, C. Albrecht4, R. Morano5, C. Entrala6, K. Van Nimwegen1|2|3|4|5|6

1 Amsterdam University Medical Center, The Netherlands
2 Erasmus Medical Center, Rotterdam, The Netherlands
3 St. Antonius Ziekenhuis, Nieuwegein, The Netherlands
4 Johnson & Johnson, Paris, France
5 Johnson & Johnson, Madrid, Spain
6 Johnson & Johnson, Breda, The Netherlands
Multiple Myeloma RRMM Treatment Management

P42 | COMPARATIVE EFFECTIVENESS OF TECLISTAMAB IN REALiTEC VS. REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN LOCOMMOTION AND MOMMENT IN TRIPLE-CLASS EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA (208 Online Views)

First match: Introduction. Teclistamab is the first approved BCMA×CD3 bispecific antibody for treating triple class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) wit ...

A. Perrot1, M. Kortüm2, R. Popat3, K. Uttervall4, M.V. Mateos5, K. Weisel6, K. Van Nimwegen7, J. Diels7, F. Ong7, R. Morano7, E. Rubio-Azpeitia7, P. Moreau8

1 Universite de Toulouse, France
2 University Hospital of Würzburg, Germany
3 University College London Hospitals NHS Foundation Trust, UK
4 Karolinska University Hospital, Stockholm, Sweden
5 Hospital Universitario de Salamanca, Spain
6 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
7 Johnson & Johnson
8 University Hospital Hôtel-Dieu, Nantes, France
Multiple Myeloma RRMM Teclistamab

B10 | HEPTA-REFRACTORY MULTIPLE MYELOMA: BIOLOGY, PROGNOSIS, AND TREATMENT (344 Online Views)

First match: ... two immunomodulatory drugs (IMiDs), two proteasome inhibitors (PIs), as well as BCMA- and GPRC5D-directed immunotherapies. This disease state can be termed “hepta-r ...

C. Riedhammer1, M. Truger2, H. Lee3, L.B. Leypoldt4|5, M. Meggendorfer2, S. Hutter2, H. Müller2, J. Mersi1, S.K. Kadel1, T. Buchwald1, R. Kosch4, M. Helal6, N. Afrin6, A. Rosenwald7, E. Gerhard-Hartmann7, A. Brioli8|9, J. Krönke8, T. Haferlach2, C. Haferlach2, K.C. Weisel4, P. Neri3, H. Einsele1, K.M. Kortüm1, J.M. Waldschmidt1, N. Bahlis3, N. Weinhold10|11, L. Rasche1|6

1 Department of Internal Medicine 2, University Hospital of Würzburg, Germany
2 MLL Munich Leukemia Laboratory, Germany
3 Arnie Charbonneau Cancer Institute, University of Calgary, Canada
4 Department of Hematology, Oncology and Bone Marrow Transplantation With Section of Pneumology, University Medical Center Hamburg-Eppendorf, Germany
5 Mildred Scheel Early Career Center, University Medical Center Hamburg-Eppendorf, Germany
6 Mildred Scheel Early Career Center, University Hospital Würzburg, Germany
7 Institute of Pathology, University of Würzburg, Germany
8 Department of Internal Medicine C, University Hospital of Greifswald, Germany
9 Hannover Medical School, Clinic for Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Germany
10 Heidelberg Myeloma Center, Department of Medicine V, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Germany
11 Clinical Cooperation Unit Molecular Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg University and German Cancer Research Center, Germany
Multiple myeloma Hepta-refractory Immunotherapy.

P40 | EFFICACY AND SAFETY OF TALQUETAMAB + TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND EXTRAMEDULLARY DISEASE: UPDATED PHASE 2 RESULTS FROM THE RedirecTT-1 STUDY WITH EXTENDED FOLLOW-UP (308 Online Views)

First match: ... ic combination of talquetamab (Tal; anti-GPRC5D×CD3) and teclistamab (Tec; anti-BCMA×CD3) in TCE RRMM is being assessed in the ongoing RedirecTT-1 trial (NCT0458642 ...

M.V. Mateos1, P. Rodríguez-Otero2, S.Z. Usmani3, S. Kumar4, J.C. Ye5, S. Atrash6, H. Magen7, H. Quach8, M.P. Chu9, S. Trudel10, J. Richter11, H. Chuah12, M. Gatt13, E. Medvedova14, S. Raza15, D.H. Yoon16, T. Ishida17, J.V. Matous18, L. Rosiñol19, K. Onodera20, C. Maffucci21, E. Scott21, C. Heuck21, J. Zhang21, T. Henninger21, L. O’Rourke21, P. Thakkar21, M. Festa21, L. Huang21, J. Zhou21, M. Takamoto21, L. Pei21, J. Lu21, N. Au21, M. Krevvata21, Y.C. Cohen7

1 University Hospital of Salamanca, Spain
2 Cancer Center Clínica Universidad de Navarra, Pamplona, Spain
3 Memorial Sloan Kettering Cancer Center, New York, USA
4 Mayo Clinic Rochester, USA
5 University of Texas, Houston, USA
6 Levine Cancer Institute-Atrium Health, Charlotte, USA
7 Tel Aviv University, Israel
8 University of Melbourne, Australia
9 Alberta Health Services, Edmonton, Canada
10 Princess Margaret Cancer Centre, Toronto, Canada
11 Mount Sinai Medical Center, New York, USA
12 Royal Perth Hospital, Australia
13 Hebrew University of Jerusalem, Israel
14 Oregon Health and Science University, Portland, USA
15 Cleveland Clinic, USA
16 University of Ulsan College of Medicine, Seoul, Korea
17 Japanese Red Cross Medical Center, Tokyo, Japan
18 Colorado Blood Cancer Institute, Denver, USA
19 Hospital Clínic de Barcelona, Spain
20 Tohoku University Hospital, Sendai, Japan
21 Johnson & Johnson
Multiple Myeloma RedirecTT-1 trial RRMM

P39 | RANDOMIZED PHASE II DOSE OPTIMIZATION STUDY OF INOBRODIB (CCS1477) IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (252 Online Views)

First match: ... domide-refractory, 71% were triple-class refractory, and 66% had received prior BCMA- or T-cell engager–directed therapy. Grade 3/4 treatment-emergent adverse event ...

E. Searle1, V. Campbell2, C. Pawlyn3, D. Vogl4, S. Holstein5, S. Gooding6, M. Jenner7, T. Creasey8, A. Chaidos9, P. Rodríguez-Otero10, F. Al-Kaisi11, A. Brearton12, S. Moore6, J. O’Nions13, T. Somervaille1, T. Knurowski14, K. Clegg14, S. Paul14, K. Frese14, N. Joseph15

1 The Christie NHS Foundation Trust, Manchester, UK
2 Western General Hospital, Edinburgh, UK
3 The Royal Marsden NHS Foundation Trust, London, UK
4 Hospital of the University of Pennsylvania, Philadelphia, USA
5 University of Nebraska Medical Center, Omaha, USA
6 Oxford University Hospitals NHS Foundation Trust, Oxford, UK
7 University Hospital Southampton NHS Foundation Trust, UK
8 Northern Centre for Cancer Care, Newcastle upon Tyne, UK
9 Imperial College Healthcare NHS Trust, London, UK
10 Clínica Universidad de Navarra, Pamplona, Spain
11 Royal Derby Hospital, UK
12 The Clatterbridge Cancer Centre, Liverpool, UK
13 University College London Hospital, UK
14 CellCentric Ltd, Cambridge, UK
15 Emory Winship Cancer Institute, Atlanta, USA
Multiple Myeloma Inobrodib RRMM

P38 | SAFETY AND EFFICACY OF TALQUETAMAB + TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM PHASE 1b OF RedirecTT-1: RESULTS WITH AN EXTENDED MEDIAN FOLLOW-UP OF 3 YEARS (244 Online Views)

First match: ... 586426; median follow-up [mFU] 20.3 mo), Tal (anti-GPRC5D×CD3) + Tec (Tec, anti-BCMA×CD3) elicited deep, durable responses in pts with triple-class exposed (TCE) RR ...

E.M. Ocio1|2, M-V. Mateos3, H. Magen4, M. Gatt5, M. Sebag6, K. Kim7, C-K. Min8, S-S. Yoon9, M.P. Chu10, P. Rodríguez-Otero11, I. Avivi4, N.A. Quijano Cardé12, M. Krevvata12, T. Henninger12, P. Thakkar12, M. Festa12, L. Huang12, J.X. Zhou12, M. Takamoto12, L. Pei12, J. Lu12, C. Maffucci12, E. Scott12, A. Oriol13, D. Morillo14, Y.C. Cohen4

1 Hospital Universitario Marqués de Valdecilla, Santander, Spain
2 Universidad de Cantabria, Santander, Spain
3 University Hospital of Salamanca, Spain
4 Tel Aviv University, Israel
5 Hebrew University of Jerusalem, Israel
6 McGill University, Montreal, Canada
7 Sungkyunkwan University School of Medicine, Seoul, Korea
8 The Catholic University of Korea, Seoul, Korea
9 Seoul National University College of Medicine, Korea
10 Alberta Health Services, Edmonton, Canada
11 Cancer Center Clínica Universidad de Navarra, Pamplona, Spain
12 Johnson & Johnson
13 Hospital Germans Trias i Pujol, Badalona, Spain
14 University Hospital Fundación Jiménez Díaz, Madrid, Spain
RRMM RedirecTT-1 Follow-up

P06 | FROM BENCH TO BEDSIDE: DRUG SENSITIVITY PROFILING TO OPTIMIZE THERAPY IN RELAPSED MULTIPLE MYELOMA (301 Online Views)

First match: ... ezomib (97.5%), carfilzomib (85%), daratumumab (82%), pomalidomide (77.5%), and BCMA CAR-T therapy (12.5%). Thirty patients received Oncopanel2 v1 and ten Oncopanel ...

R. Cassano Cassano1|2, T. Martins3, D. Coffey4, G. Buda5, S. Galimberti5, L.M.A. Melillo2, R. Donnelly1, M. Kwok1, D. Green1, R. Banerjee1, K. Cicero1, T. Gooley1, R. Silbermann4, P. Becker6, A.J. Cowan1, D. Dima1

1 Fred Hutchinson Cancer Center, Seattle, USA
2 Policlinico Riuniti Foggia, Hematology Division, Italy
3 University of Washington, Seattle, USA
4 University of Miami Hospital and Clinics-UHealth Tower, USA
5 University of Pisa, Italy
6 OHSU Hospital, Portland, USA
Relapsed Multiple Myeloma CART Drug Sensitivity

B07 | PROGNOSTIC ROLE OF STANDARDIZED (18)F-FDG-PET/CT AND WB-DW-MRI IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS RECEIVING T CELL-REDIRECTING THERAPIES (340 Online Views)

First match: ... s thereafter. Results. 68 pts were enrolled until August 2025. 40 received anti-BCMA CAR-T, 13 anti-BCMA BsAbs and 15 anti-GPRC5D BsAbs. Median number of prior line ...

M. Talarico1|2, A. Cattabriga1|3, L. Pagnini1|4, V. Solli1|2, S. Barbato1|2, S. Ghibellini1|2, S. Masci1|2, E. Manzato1|2, M. Puppi1|2, M. Iezza1|2, K. Mancuso1|2, L. Pantani2, P. Tacchetti2, C. Terragna2, M. Ursi5, E. Maffini5, F. Bonifazi5, S. Brocchi3, C. Mosconi1|3, C. Nanni4, S. Fanti1|4, E. Zamagni1|2

1 Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Italy
2 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Italy
3 Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
4 Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
5 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
RRMM Functional Imaging T-cell Therapy
1 - 21 of 21 items
Navigate
For Authors
For Reviewers
For Advertisers
Education
Privacy
More
Copyright © 2026 by the Ferrata Storti Foundation | Web design ￫ | Development ￫
ISSN 0390-6078 print | ISSN 1592-8721 online